SS-31 (Elamipretide)
SS-31, also known as elamipretide or Bendavia, is a mitochondrial-targeted tetrapeptide that selectively concentrates in the inner mitochondrial membrane. It stabilizes cardiolipin, a phospholipid essential for electron transport chain efficiency, and has been studied in multiple Phase 3 clinical trials for mitochondrial dysfunction.
Talk with an Aspire clinician about whether SS-31 (Elamipretide) may be appropriate for your health goals.
Text Us NowElamipretide - Mitochondrial Cardiolipin Stabilizer
SS-31 (D-Arg-dimethylTyr-Lys-Phe-NH2), also known as elamipretide or Bendavia, is a synthetic tetrapeptide with a unique property: it carries a net positive charge that drives it to concentrate in the inner mitochondrial membrane at concentrations 1,000-5,000 times higher than in the cytoplasm. Once there, it binds to cardiolipin, a phospholipid that is essential for the structural organization and function of the electron transport chain complexes.
Elamipretide has advanced further through clinical trials than most peptides in the longevity and cellular health space. It has been studied in Phase 2 and Phase 3 trials for primary mitochondrial myopathy (Barth syndrome), heart failure, age-related macular degeneration, and renal function. While it has not yet received FDA approval, the depth of clinical investigation distinguishes it from many compounds in the peptide therapy space. Research focuses on its ability to restore mitochondrial efficiency in conditions where mitochondrial dysfunction is a primary driver of disease.
Aspire offers SS-31 (elamipretide) through licensed U.S. 503A compounding pharmacies. Given its clinical research profile, treatment is prescribed by Aspire clinicians with appropriate evaluation and monitoring, with particular attention to patients with concerns related to mitochondrial function, energy production, and age-related cellular decline.

Proposed Mechanism of Action
Cardiolipin is a unique phospholipid found exclusively in the inner mitochondrial membrane. It is essential for the proper assembly and function of electron transport chain (ETC) complexes and the ATP synthase supercomplex. As cardiolipin becomes oxidized or depleted with age and disease, ETC complexes destabilize, electron transfer becomes inefficient, reactive oxygen species (ROS) production increases, and ATP synthesis declines. This creates a vicious cycle where mitochondrial dysfunction produces more oxidative damage, which further damages mitochondria.
SS-31 breaks this cycle by binding to cardiolipin and restoring its structural role in organizing ETC complexes. Research has shown that SS-31 reduces electron leak at Complex I and Complex III, decreases mitochondrial ROS production, improves the efficiency of ATP synthesis, and restores mitochondrial membrane potential. Unlike antioxidants that scavenge ROS after they are produced, SS-31 addresses the upstream structural problem that causes excess ROS production in the first place, making it a fundamentally different approach to mitochondrial health.
What SS-31 (Elamipretide) Is Being Explored For
These are the primary areas where SS-31 (Elamipretide) has been studied or discussed in the context of peptide therapy. Research depth varies by area.
How SS-31 (Elamipretide) Is Offered
SS-31 (Elamipretide) is available through Aspire in the following formulations, all compounded by licensed U.S. 503A pharmacies. Your clinician will recommend the appropriate form based on your goals and treatment plan.
Text our team anytime during business hours.
Monday through Friday, 9:30 AM - 6:00 PM.
We're here to help you understand your options.
How Treatment Works
Peptide therapy at Aspire follows a clinician-guided process. SS-31 (Elamipretide) is not available for self-prescribing or anonymous purchase.
Often Explored Alongside SS-31 (Elamipretide)
These compounds are frequently discussed in similar clinical contexts or combined in treatment protocols.
SS-31 (Elamipretide) FAQ
SS-31/elamipretide has one of the most advanced clinical research profiles in the peptide space, with multiple Phase 2 and Phase 3 trials completed or ongoing. While it has not yet received FDA approval, it has received Fast Track designation from the FDA for Barth syndrome. The clinical trial data provides a more robust evidence base than is available for most compounded peptides.
Ready to explore SS-31 (Elamipretide)?
Talk with an Aspire clinician about your goals and whether SS-31 (Elamipretide) therapy may be appropriate for you.
Text Us Now

